Our research team has been working on the discovery of new cancer immunotherapy that can treat immunologically “cold tumor”. Our team found that in cold tumor, tumor-associated macrophages (TAMs) were specifically inactive and did not exert their antigen presentation function.
Our proprietary drug delivery system “T-ignite®” can bind TAMs specifically and deliver functional drug candidates to reprogram TAMs and to activate T cell. We aim to overcome intractable cold cancer that is refractory to existing treatments such as immune checkpoint inhibitors by developing novel combination immunotherapies utilizing T-ignite and other immunotherapies and/or molecular-targeted therapies.